A Pilot Trial of a CEA-TRICOM Based Vaccine and Radiation to Liver Metastasis in Adults With CEA Positive Solid Tumors

Date de début de l'étude : 20 avril 2004

* INCLUSION CRITERIA Solid Tumors expressing CEA positive cancer with radiographically visible metastatic liver lesions. Tumor that has been shown to express CEA by positive immunohistochemical techniques (staining of at least 20% of cells will be considered positive) or have had an elevated serum CEA greater than 5 ng/ml at any point during their disease course. Completed at least one chemotherapy regimen for metastatic disease. 18 years of age or greater. Life expectancy greater than or equal to 6 months. Able to understand and give informed consent. ECOG performance status of 0 - 1. Serum creatinine within the institution limits of normal OR creatinine clearance on a 24 hour urine collection of greater than or equal to 60 mL/min, AST less than or equal to twice the institution upper limits of normal. Total bilirubin less than the upper level of normal for that particular institution and if patient has Gilbert's syndrome, is bilirubin less than or equal to 3.0. Vaccinia-naive or vaccinia immune. Recovered completely from any reversible toxicity associated with recent therapy. Typically this is 3-4 weeks for patients who most recently received cytotoxic therapy except for the nitrosoureas and mitomycin C for which 6 weeks is needed for recovery. At least 4 weeks after cytotoxic therapy with complete recovery of reversible toxicity. Hematological eligibility parameters (within 16 days of starting therapy): Granulocyte count greater than or equal to1,500/mm(3). Platelet count greater than or equal to 100,000/mm(3). Hgb greater than or equal to 8 Gm/dL. Absolute lymphocyte count greater than or equal to 400/mm(3). PT/PTT within the institution limits of normal. Prior Immunotherapy will be allowed Serum Beta-HCG less than 5.0 microIU/mL in females (with child bearing potential). EXCLUSION CRITERIA Patients should have no evidence of being immunocompromised as listed below. * Human immunodeficiency virus positivity due to the potential for decreased tolerance and may be at risk for severe side effects * Autoimmune diseases such as, Addison's disease, Hashimoto's thyroiditis, or systemic lupus erythematous, Sjogren syndrome, scleroderma, myasthenia gravis, Goodpasture syndrome active Grave's disease. Altered immune function in prospective participants will be assessed through a thorough history and physical examination. Any clinical suspicion of autoimmune dysfunction will be worked up before enrollment on to the study. This requirement is due to the potential risks of exacerbating autoimmunity * Hepatitis B or C positivity * Prior radiation to greater than 50% of all nodal groups * Prior whole liver radiation * Concurrent use of systemic steroids, except for physiologic doses for systemic steroid replacement or local (topical, nasal, or inhaled) steroid use. Steroid eye drops are contraindicated for at least 2 weeks prior vaccinia vaccination and at least 4 weeks post vaccinia vaccination. * Prior splenectomy History of allergy or untoward reaction to prior vaccination with vaccinia virus or to any component of the vaccinia vaccine regimen. Pregnant or breast-feeding women. Recombinant vaccinia vaccination should not be administered if any of the following apply to either recipients, or for at least three weeks after vaccination (i.e., until the scab has separated from the skin and the underlying skin has healed), their close household contacts (close household contacts are those who share housing or have close physical contact): persons with active or a history of eczema or other eczematoid skin disorders; those with other acute, chronic or exfoliative skin conditions (e.g., atopic dermatitis, burns, impetigo, varicella zoster, severe acne, or other open rashes or wounds) until condition resolves; pregnant or nursing women; children 5 years of age and under; and immunodeficient or immunosuppressed persons (by disease or therapy), including HIV infection. Serious intercurrent medical illness which would interfere with the ability of the patient to carry out the treatment program, including, but not limited to, inflammatory bowel disease, Crohn's disease, ulcerative colitis, or active diverticulitis. Known brain metastasis, history of seizures, encephalitis, or multiple sclerosis. Concurrent chemotherapy. Serious hypersensitivity reaction to egg products. Clinically significant cardiomyopathy requiring treatment. Patients with cardiac disease that have fatigue, palpitation, dyspnea or angina with ordinary physical activity (New York Heart Association class 2 or greater) are not eligible. Patients with pulmonary disease that have fatigue or dyspnea with ordinary physical activity are not eligible. Patients who have objective evidence of congestive heart failure by physical exam or imaging are not eligible. Chronic liver disease including end stage cirrhosis, or chronic active hepatitis as indicated by surface antigen or core antibody.